Site for I4V-MC-JAJD - A Randomized Controlled Pragmatic Phase 3b/4 Study of Baricitinib in Patients with Rheumatoid Arthritis
Brief description of study
Site for Study I4V-MC-JAJD (JAJD) is a Phase 3b/4, multicenter, randomized, parallel-group, active-controlled, pragmatic, event-driven study to evaluate the effects of baricitinib (2 mg and 4 mg daily) compared with tumor necrosis factor (TNF) inhibitors (administered according to approved local labeling) on risk of VTE and other key safety endpoints in patients with RA receiving routine clinical care. Consistent with the pragmatic intent of this study, once randomized, treatment will be provided through mechanisms available to patients in routine care and will be open-label for patients and study-site personnel.
Clinical Study Identifier: s20-00001
ClinicalTrials.gov Identifier: NCT04086745
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
